Angiotensi

Angiotensin Receptor Blockers May Prevent Epilepsy

Angiotensin receptor blockers (ARBs) are associated with a lower incidence of new-onset epilepsy compared with other antihypertensive agents in patients with hypertension, according to a study published in JAMA Neurology. “This is incredibly exciting because we do not currently have any medicines that prevent epilepsy,” said Kimford Meador, MD, Stanford University School of Medicine, Palo Alto, California. “I hope these initial findings lead to randomised clinical trials.” While epilepsy is often diagnosed during childhood, >1% of people aged >65 years are diagnosed with the recurring se...

High-dose corticosteroids may increase risk of CMV reactivation in patients with COVID-19 pneum...

A study published in PLOS One showed that reactivation of the cytomegalovirus (CMV) was significantly higher in critically ill patients with COVID-19 pneumonia receiving high-dose corticosteroid therapy compared with patients who did not receive cort...

Loop diuretic utilisation with or without heart failure: impact on prognosis.

BACKGROUND & AIMS Many patients are prescribed loop diuretics without a diagnostic record of heart failure. Little is known about their characteristics and prognosis. METHODS Glasgow regional health records (2009-2016) were obtained for adul


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Update of
4:48

Update of EULAR recommendations for the treatment of Systemic Sclerosis

Presenter: Francesco Del Galdo
Internal Medicine
EULAR 2024
Promising
5:13

Promising directions in the treatment of Psoriatic Arthritis

Presenter: Rik Lories
Internal Medicine
EULAR 2024
Interstiti
6:06

Interstitial Lung Disease: from diagnosis to management

Presenter: Anna-Maria Hoffmann-Vold
Internal Medicine
EULAR 2024
What is Ne
7:12

What is New : Osteoporosis in Rheumatology

Presenter: Willem Lems
Internal Medicine
EULAR 2024
Effectiven
5:48

Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

Presenter: Gerd Horneff
Internal Medicine
EULAR 2024
Early and
9:21

Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients

Internal Medicine
EULAR 2024
Fatigue, P
11:11

Fatigue, Pain and Opioids in Rheumatological Diseases

Presenter: Rene Westhovens
Internal Medicine
EULAR 2024
Cardiovasc
3:54

Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases

Presenter: Anja Strangfeld
Internal Medicine
EULAR 2024
Update on
5:00

Update on EULAR/ACR Project: Risk Stratification in patients with arthralgia suspicious for progression to RA

Presenter: Annette H. M. van der Helm van Mil
Internal Medicine
EULAR 2024
Difficult
9:43

Difficult Questions in Osteoporosis

Presenter: Roland Chapurlat
Internal Medicine
EULAR 2024
Secukinuma
6:32

Secukinumab versus standard-of-care in axial spondyloarthritis

Presenter: Denis Poddubnyy
Internal Medicine
EULAR 2024
Lupus: wha
10:48

Lupus: what's on the horizon?

Presenter: David Isenberg
Internal Medicine
EULAR 2024
Overview o
2:48

Overview of the 2024 EAS Congress

Presenter: Kausik K Ray
Cardiology : Atherosclerosis
EAS 2024
Metabolic
6:12

Metabolic Reprogramming in Autoimmunity

Presenter: Valentina Pucino
Internal Medicine
EULAR 2024
Rheumatoid
6:13

Rheumatoid Arthritis Prevention: what have we learnt, and where do we go next?

Presenter: Raphael Micheroli
Internal Medicine
EULAR 2024
6:52

"Asymptomatic" Hyperuricemia: Innocent bystander or menacing foe?

Presenter: Francisca Sivera
Internal Medicine
EULAR 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology
Once-weekl
1:17

Once-weekly semaglutide in people with HFpEF and obesity

Presenter: Mikhail Kosiborod
Cardiology